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Abstract 
 
 Aspartate transcarbamoylase (ATCase) catalyzes the reaction between 
carbamoyl phosphate (CP) and aspartate to form N-carbamoyl-L-aspartate (CA) 
and inorganic phosphate (Pi). In Escherichia coli, it catalyzes the committed step 
of pyrimidine nucleotide biosynthesis. It is heterotropically activated by ATP, and 
is inhibited by CTP and UTP. X-ray studies have revealed valuable information 
regarding the catalytic mechanism, as well as insights into the homotropic and 
heterotropic interactions. However, localized changes and changes under 
biological conditions are difficult to study this way. The expression of a viable 
and active fluorescent mutant of ATCase containing a 7-hydroxycoumarin amino 
acid will allow for studies of the signal transduction process involved in the 
negative cooperativity observed in the binding of allosteric effectors. The 
fluorescent intensity should correlate to the binding of the NTPs at close 
proximity to the unnatural fluorescent amino acid. Furthermore, TR-SAXS will be 
used to observe transiently stable intermediates of ATCase formed during the T to 
R transition. This method’s typically observed poor time resolution caused by the 
dead time of the stopped-flow mixer will be addressed by the used of a caged 
aspartate, 4-methoxy-7-nitroindolinyl-L-aspartate, synthesized in this work. 
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Chapter 1. Introduction 
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Aspartate Transcarbamoylase 
Understanding the coordination and regulation of biosynthetic pathways in cells is 
important for the development of methodologies which allow directed control of cellular 
reactions when natural mechanisms have been altered by a disease such as cancer. 
Cellular self-regulation is usually accomplished by three general mechanisms: genetic 
and metabolic, which adjust the number or the type of enzyme molecules, and allosteric, 
which is achieved by modifying enzyme’s activity. For allosteric proteins, the movement 
of entire domains or subunits may be involved in the transition from an inactive to an 
active form.  
Aspartate transcarbamoylase (ATCase) has been studied since 1963,1 due to its 
importance in understanding the control and regulation of metabolic pathways by 
allosteric enzymes. ATCase catalyzes the committed step in de novo pyrimidine 
biosynthesis, which involves the condensation of carbamoyl phosphate (CP) and L-
aspartate (Asp) to form N-carbamoyl-L-aspartate (CA) and phosphate (Pi) (Figure 1.1).2,3 
Mammalian ATCase is part of a multifunctional complex CAD, which contains 
carbamoyl phosphate synthetase (CPSase), ATCase, and dihydroorotase (DHOase) on 
one polypeptide chain. Escherichia coli (E. coli) ATCase, an easy isolatable enzyme, is a 
commonly used to model to the mammalian enzyme ATCase, despite the differences, 
because the two enzymes display 43% sequence homology, including all of the residues 
in the active site residues thought to be important for function.4  
The holoenzyme (Mr 310,000) contains six catalytic chains (Mr 34,000 each) 
organized into two catalytic trimers, and six regulatory chains (Mr 17,000 each) organized  
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Figure 1.1. ATCase catalyzes the reaction between carbamoyl phosphate and L-aspartate 
to form N-carbamoyl-L-aspartate and inorganic phosphate via a proposed tetrahedral 
intermediate. A specific inhibitor of ATCase N-(phosphonacetyl)-L-aspartate (PALA) is 
shown below the tetrahedral intermediate.  
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into three regulatory dimers.5,6  The catalytic chain is coded for by the pyrB gene, and 
this chain is insensitive to allosteric effectors. The regulatory chain, which is coded for by 
the pyrI gene, has no catalytic activity and binds to allosteric effectors (Figure 1.2).7 
Each catalytic chain folds into two domains, the carbamoyl phosphate (CP) 
domain which consists of residues 1-135 and 292-310, and the aspartate (Asp) domain 
that consists of residues 136-291. The six active sites in the holoenzyme are made up of 
residues from two adjacent catalytic chains within the trimer.8,9 Using crystal structures, 
important residues in each active site have been identified such as Ser52, Thr53, Arg54, 
Thr55, Arg105, His134, Gln137, Arg167, Arg229, and Gln231 of one catalytic chain and 
Ser80 and Se84 of the adjacent catalytic chain (Figure 1.3).10-13 The actual importance of  
these residues have been verified by site-specific mutagenesis.14  
The regulatory chain contains two domains, the N-terminal allosteric domain, 
containing the allosteric site, and the C-terminal zinc domain, in which a Zn(II) cation is 
tetrahedrally coordinated to four cysteine residues.15 The zinc domain is important in 
mediating interactions between the catalytic and the regulatory subunits.16 The allosteric 
site binds the allosteric effectors ATP, CTP, and UTP. ATP activates the enzyme, and 
both CTP alone, and UTP in the presence of CTP, inhibit the enzyme.17, 18  
The regulatory binding site is located approximately 60Å from the active site of 
the catalytic chain.19 ATP and CTP both bind this site in the anti-conformation. Both the 
ribose and nucleobase moieties of ATP and CTP bind in similar locations within the 
allosteric site, although the ribose of ATP protrudes deeper into the enzyme than the 
ribose of CTP.14,20 The specific interactions of CTP with the E. coli holoenzyme include 
Val91r, Lys94r, Arg96r, Asp19r, His20r, Val9r, Lys56r, Lys17r, Ala11r, Ile12r,  
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Figure 1.2. The quaternary structure of the E. coli ATCase holoenzyme based upon PDB 
entry 1D09.10 The individual catalytic and regulatory chains are shown in different 
colors.  (A) The holoenzyme viewed along the molecular three-fold molecular axis. The 
C4, C5, and C6 are positioned below C1, C2, and C3 and can be viewed better in B. The 
regulatory dimmers are composed of chains R1/R6, R2/R4, and R3/R5. The catalytic 
trimers are stacked upon each other and are non-covalently bridged by the regulatory 
dimers.21 (B) The holoenzyme viewed along one of the three two-fold molecular axes.21 
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Figure 1.3. Schematic diagram of the PALA binding site in the C1 chain of ATCase. 
PALA was found to block proliferation of mammalian cells in cultures,24,25 and was also 
shown to inhibit the growth of colonic cancer cells.25 The residues shown are those which 
are hydrogen bound (dotted lines) to PALA. LIGPLOT26 was used to construct this 
diagram with the PDB entry 1D09.10 
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Tyr98r.14,22 The only difference between UTP and CTP is the presence of a carbonyl 
group at position 4 in place of the exocyclic amine, and the subsequent protonation of the 
nitrogen at position 3. Thus, the UTP:ATCase interaction CTP:ATCase interaction 
differences might be based on the interactions of the nitrogen at position 3 and the amino 
group with Ile12r.27  
 ATP, on the other hand, forms specific interactions with Asn84r, Val91r, Lys94r, 
Leu58r, Asp19r, Val9r, Lys60r, Glu10r, Ala11r, Ile12r, and Tyr84r.14 The binding of 
ATP causes an expansion in the stacked R chains of the regulatory dimer, leading to an 
increase in allosteric domain size when compared with the apo- regulatory dimer, or with 
the CTP bound enzyme.28  
 
Catalytic Mechanism 
A general acid base catalytic mechanism was thought to be involved in the 
ATCase carbamoylation reaction. A general base, in this case His134, would remove a 
proton from the α-amino of aspartate, and an acid would interact with the carbonyl group 
of CP, in order to make a nucleophilic attack more feasible.29 However, mutagenesis 
studies of His134 showed that this residue, although important, is not essential to the 
catalysis since only a 20-fold reduction in activity was observed compared to the wild-
type enzyme.30 Today, it is more clear that ATCase’s catalytic rate enhancement is not 
just the function of individual residues, but more due to positioning, orientation, and 
stabilization of substrates, intermediates, and products.10  
The reaction catalyzed by ATCase follows a preferred-ordered mechanism, in 
which CP binds first to the enzyme first. This binding induces a small conformational 
 8 
change which forms the aspartate-binding pocket. Then, binding of aspartate generates a 
large conformational change as ATCase moves from the T to the R state, bringing the 
two substrates together.31 After the nucleophilic attack of the CP carbonyl group by the 
α-amino group of aspartate, a tetrahedral intermediate forms. This collapses to form CA 
and Pi,31 and lastly CA is released from the active site, followed by Pi.31 
 
Allosteric Mechanism 
Among the various models used to explain binding and activity curves of 
allosteric enzymes, the Monod, Wyman, Changeux (MWC) model33 has been the most 
influential. The enzyme, in this model, must have two or more identical subunits and two 
different conformational states. Based on the MWC theory, the conformational transition 
involves spontaneous interconversion between the T and R states in the absence of a 
ligand. Low substrate affinity and activity are associated with the T state, while high 
affinity and activity are related to the R state. Ligands can bind to both states, but have a 
higher affinity for R, which is stabilized after binding. The MWC proposes that the 
enzyme exists either in the T or R state. They are in equilibrium, and the transition 
between the two conformations is by a concerted mechanism in the entire enzyme rather 
than in individual subunits. 
Another popular model is the Koshland, Nemethy, and Filmer (KNF) model, 
which states that an enzyme can exist in a hybrid conformation.34 Ligand binding affects 
the state of the bound subunit, but the arrangement of the other subunits is not altered. 
The resulting conformational change, due to binding of the ligand, can increase or 
decrease the subunit’s affinity for the ligand, leading to cooperativity.  
 9 
Data analyzed from small angle X-ray scattering (SAXS),35,36 sedimentation 
centrifugation,37 gel chromatography,38 and X-ray crystallography have shown a large 
change in conformation within the ATCase holoenzyme, due to the binding of substrates 
and the bisubstrate analog PALA. Therefore, it has been established that ATCase exists 
in at least two structurally and functionally different conformations, the unliganded T 
state, and the liganded R state (Figure 1.4). The proposed T to R state equilibrium for 
wild-type ATCase is strongly shifted to the T state, being of the order of 1% since 
L=25038 or L=70,40 where L is the allosteric constant L=[T0]/[R0] in the absence of 
substrate. ATCase exhibits changes in the quaternary structure, such as an 11 Å 
elongation along the molecular two-fold axis, a 10° rotation about the three-fold axis of 
the catalytic subunits, and 15° rotations of the regulatory chains about their respective 
two-fold axes.12 On the tertiary level, a domain closure that consists of 50’s loop 
(residues 50-55), 80’s loop (residues 76-85), and 240’s loop (residues 225-245) shifting 
2-3, 7, and 10 Å respectively to enclose the substrates CP and L-aspartate within the 
active site, causing the required cooperativity between the CP and Asp domains.41 
 The T state is stabilized by interdomain interactions between catalytic chains C1 
and C4 using hydrogen bonding interactions such as Glu239 (C1) with Lys164 and 
Tyr165 (C4), and Tyr240 (C1) with Asp271 (C4), 12 and the catalytic and regulatory 
interaction of chains C1 and R4. In the latter, the 240’s loop of C1 interacts with residues 
143-149 of R4, and a salt bridge between Asp236 of C1 and Lys143r of R4 is also 
observed. When transitioning to the R state, the 240’s loop is relocated so the enzyme 
loses the C1:C4 and C1:R4 contacts.42 The mentioned domain closure of the CP and Asp 
domains stabilizes the R state, in which Glu50 of the CP domain is hydrogen bound to  
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Figure 1.4. The R state (A) and T state (B) of ATCase. The T state structure was made 
using PDB code 1RAA43 and the R state structure was made using PDB code 1D09.10  
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Arg167 and Arg234 of the Asp domain, and Gln133 and His134 of the CP domain 
interact with Ser171 of the Asp domain. Mutation of any of these residues results in R 
state destabilization.30, 44-46  
 
Cooperativity  
 Homotropic cooperativity: 
The ATCase holoenzyme exhibits sigmoidal kinetics due to its positive 
cooperativity with respect to aspartate.17 Recent site-specific mutagenesis experiments47 
showed that the binding of CP in the proper orientation is required for the conformational 
change needed to create the high-affinity Asp binding site, inducing homotropic 
cooperativity. In the case of CP, it was believed that it also bound cooperatively to the 
enzyme; however the apparent cooperativity is due to the ordered binding of the 
substrates.48 Time-resolved X-ray scattering showed that binding of Asp to the 
ATCase:CP complex causes the enzyme to transition to the R state, staying in this 
conformation until all the substrates have been exhausted.  In studies using a hybrid 
ATCase holoenzyme with only one functional active site,49 the transition to the R 
conformation in the hybrid ATCase does occur after substrates binding or bisubstrate; 
therefore, the binding of PALA to the one active site of the hybrid ATCase follows the 
concerted MWC model, and brings about the full allosteric transition.33 
Heterotropic cooperativity: 
 The end product of the purine pathway, ATP, activates ATCase and either CTP 
alone or a UTP with CTP inhibit the enzyme.17,18 Based on X-ray crystallography, ATP 
and CTP alone will not cause the full T to R transition.50 An ATP:ATCase complex 
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structure shows a 0.4 Å shift in vertical separation between the upper and lower catalytic 
subunits towards the R state, and an R state structure of ATCase bound to CTP presents a  
vertical separation between catalytic subunits of 0.5 Å towards the T state.20 However, 
these allosteric effectors influence the activity and affinity of ATCase by stabilizing the T 
or R state.51  
 ATCase displays negative cooperativity for the binding of CTP; after one CTP is 
bound the next becomes more difficult to bind.52 A high affinity site and a low affinity 
binding site exists within the regulatory dimer.52,53 The MWC model cannot explain the 
negative cooperativity to the regulatory chain but the KNF model seems to work better.34 
Using KNF theory, the binding of CTP induces a local conformational change within the 
subunit and causes cooperative interactions between the subunits making it more difficult 
for subsequent CTP molecules to bind, but enhanced affinity for UTP.54 
 
Use and incorporation of unnatural amino acids into proteins 
Developments in the incorporation of unnatural amino acids into proteins 
 Site-directed mutagenesis, in which one specific amino acid can be substituted by 
any of the other naturally occurring amino acids, has given us the opportunity to probe 
the principles that rule protein structure and folding, biomolecular recognition, and 
catalysis. However, changes in protein structure are limited to only the 20 natural amino 
acids, which may not properly address many structure-function questions.55 On the other 
hand, incorporation of analogues beyond the genetic code such as spin labels, affinity 
labels, and redox-active or metal-chelating amino acids can expand biophysical studies 
on proteins.55  
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Currently, many tools which allow for the incorporation of unnatural amino acids 
into proteins are available. Peptide synthesis, for example, has been used to replace 
original amino acids in biologically active peptides such as S-peptide.56 Advances in the 
segment synthesis-condensation approach, in particular, have served as tools to 
synthesize small proteins with novel amino acids in milligram quantities.57, 58 A limitation 
in this method is size, since only peptides and small proteins can be produced due to the 
decreasing yield and purity in the synthesis of larger proteins. 
A similar approach is protein semisynthesis, which involves the ligation of a 
synthetic peptide, containing the unnatural amino acid, to a protein fragment in order to 
produce the full-length protein of ≤30 kDa in size.59 A classical example is the 
investigation of the effects of the “second shell” on the redox potential of an iron-sulfur 
protein by systematic substitution of non-coded amino acids.60 However, the substitutions 
allowed by this method are confined largely to the N and C termini.  
Moreover, a variety of unnatural side chains have been introduced into proteins 
by chemical modifications of unusually reactive and solvent-accessible amino acid side 
chains. One such example is the alteration of substilisin to create thiol-substilisin.61 
ATCase has also been subjected to chemical modifications to produce a pyrene-labeled 
enzyme for fluorescent studies.62 A wide limitation to this technique is the fact that 
chemical modification can lead to nonselective and nonquantitative alteration in the 
protein.  
An alternative method is the use of functional analogues of aminoacyl transfer 
RNA’s (tRNAs) to incorporate modified amino acids as biophysical probes into proteins 
synthesized in vitro.63, 64 Coupled with this technique, chemically misacylated tRNAs 
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have been used to incorporate unnatural amino acids into dipeptides.65 Some drawbacks 
of this technique are the low yields in cell-free translation systems, as well as the 
complex creation of the modified aminoacyl-tRNA. However, further developments in 
the biosynthetic approach, including the introduction of an in vivo technique, have 
dramatically improved the applicability of incorporation of unnatural amino acids into 
proteins. 
 
Site-Specific incorporation of unnatural amino acids. Site-directed mutagenesis and the 
expanded genetic code.   
 The first general method66 of unnatural amino acids published by the Schultz lab 
consisted of replacing the codon of the amino acid of interest by the nonsense codon, 
TAG, using oligonucleotide-directed mutagenesis. A suppressor tRNA directed against 
this codon was then chemically aminoacylated in vitro with the desired analogue. The 
aminoacylated tRNA was added to an in vitro protein synthesizing system, where it 
directs the insertion of the unnatural amino acid at the target site of the protein.55 
 From the least efficient in vitro method, incorporation of unnatural amino acids 
was taken to the next step. Expression in living organisms, which allows access to higher 
yields, fidelity, and technical ease, has been utilized.67 Introducing an unnatural amino 
acid using an in vivo system67 requires a unique tRNA-codon pair, an aminoacyl-tRNA 
synthetase, and high intracellular levels of the unnatural amino acid.  For an in vivo 
system, it is very important to create an orthogonal tRNA, which means that it cannot be 
recognized by the endogenous aminoacyl-tRNA synthetases of the host while still 
functioning efficiently in translation. Moreover, an orthogonal aminoacyl-tRNA 
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synthetase, which does not aminoacylate any endogenous tRNAs, is also required and 
this synthetase should only aminoacylate the orthogonal tRNA with the desired unnatural 
amino acid. Finally, the unnatural amino acid must be easily transported into the 
cytoplasm when added to the medium, and it cannot be a substrate for the endogenous 
tRNA synthetases if it is incorporated in response to its cognate codon. 
 In order to achieve the required orthogonality, the Schultz Lab focused on 
archaea as the source of tRNA/synthetase pairs for use in E. coli. These archaeal 
aminoacyl-tRNA synthetases are more similar to eukaryotic than prokaryotic synthetases, 
but the archaeal ones can be expressed in their active forms very efficiently in E. coli. 
From these archaeal bacteria, the first tRNA/synthetase pair generated was derived from 
Methanococcus jannaachii.68 This M.jannaschii tyrosyl-tRNA synthetase (Mj TyrRS) has 
a minimalistic anticodon loop binding domain that should make it possible to change the 
anticodon loop of its cognate tRNA to CUA without losing affinity; furthermore, this 
synthetase does not have an editing mechanism.  
Due to the small degree of aminoacylation of a functional amber suppressor M. 
jannaschii tRNAtyrCUA (Mj tRNAtyrCUA), it was necessary to evolve the orthogonal tRNAs 
in E. coli from heterologous precursors.69 The general method67 consists of using a 
library of tRNA mutants, which are from a heterologous suppressor tRNA, in a 
combination of negative and positive selections with and without cognate synthetases, 
respectively (Figure 1.5a). In order to create the tRNA library for Mj tRNAtyrCUA, eleven 
nucleotides that do not interact directly with Mj TyrRS were randomly mutated. The 
tRNA library along with a mutant barnase gene is introduced into E. coli for the negative 
selection. In the barnese gene, the amber nonsense codons are introduced at sites  
 16 
 
A  
B  
 
Figure 1.5.  A) Directed evolution of orthogonal amber suppressor Mj tRNAtyrCUA in E. 
coli by alternating negative and positive selection. 67 B) The orthogonal amber suppressor 
Mj tRNAtyrCUA with mutated nucleotides in red.67 
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permissive to substitution by any other amino acids. Therefore, when one of the 
suppressor tRNA library is not orthogonal, in other words, aminoacylated by an E. coli 
synthetase, the amber codons are suppressed and the ribonuclease barnase is produced 
causing cell death. Only the cells containing not functional or orthogonal tRNAs will 
survive. In the next step, the tRNAs from surviving cells are applied in a positive 
selection in the presence of the cognate heterologous synthetase and a β-lactamase gene 
with an amber codon at a permissive site. Therefore, tRNAs are selected in the basis of 
suppressing the amber codon and producing active β-lactamase, in other words, they 
function in translation and they are good substrate for the cognate synthetase. Once a 
functional orthogonal tRNA (Figure 1.5b) was produced, it was also necessary to alter the 
substrate specificity of Mj TyrRS so it charges the orthogonal tRNA with only the 
unnatural amino acid. Again the use of a mutant library and a combination of negative 
and positive selections was the strategy68, 70 to evolve the synthetase to aminoacylate the 
cognate tRNA only with the desired unnatural amino acid, being the main goal of this 
evolution to be independent of the structure of the desired amino acid (Figure 1.6). 
Synthetase libraries were generated by randomly mutating six different residues of the 
binding pocket based on X-ray data obtained from the synthetase complexed with it 
cognate amino acid. The positive selection in E. coli consisted on resistance to 
chloroamphenicol due to suppression of an amber mutation at a permissive site in the 
chloroamphenicol acetyl transferase (CAT). Therefore, those cells with a mutant 
synthetase that aminoacylates the tRNA with the unnatural amino acid or an endogenous 
one will survive. Plasmids with active mutant synthetases are then transformed into 
negative selection strains, with which selections are carried out in the absence of  
 18 
 
 
 
 
 
 
 
 
Figure 1.6. A general positive and negative selection scheme to evolve synthetases in E. 
coli for an unnatural amino acid.66 
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unnatural amino acid. Therefore, those cells containing synthetases that incorporate 
endogenous amino acids in response to amber codons in the barnese gene will die. 
Several rounds of positive and negative selection are necessary to yield mutant 
aminoacyl-tRNA synthetases that specifically introduced the desired unnatural amino 
acid in response to the amber codon. 
 
Methodology and Application of a genetically encoded fluorescent amino acid. 
Studies of protein structure and function have greatly benefited from the 
introduction of fluorescent probes in proteins; for example, the green fluorescent protein 
is an excellent tool for protein expression, localization and biomolecular interactions. 
However, it has limitations such as fusions only at the C- or N- terminus, low sensitivity 
to the environment, and possible perturbations due to its size.71 Other approaches to 
introduce fluorescent probes are: chemical methods in which reactive accessible residues 
are necessary,72 biosynthetic methods that use chemically misacylated tRNA and are 
carried out in vitro with poor yields,55 and the most efficient and versatile method that 
involves genetically encoding of a fluorescent analogue in living organism. 
 The Schultz Lab generated an orthogonal tRNA/aminoacyl-tRNA synthetase pair 
by evolving a mutant Mj tRNAtyrCUA/ Mj TyrRS pair to selectively introduce L-(7-
hydroxycoumarin-4-yl) ethylglycine  1 (Figure 1.7a,b) into proteins in E. coli in response 
to an amber codon TAG.71 The first step was to create a Mj TyrRS library (pBK-lib5) in 
which His70 was mutated to Gly and Ala67 stay as Ala or mutated to gly in order to 
increase the size of the active site to accommodate the large coumarin side chain. Then 
six residues that bind tyrosine, Tyr-32, Leu-65, Phe-108, Gln-109, Asp 158, and Leu-162, 
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were randomly mutated. This library was then subjected to the positive and negative 
selections described in the previous section. In the positive selection, cells are dependent 
on the suppression of an amber codon at a permissive site in CAT gene when 
cotransformed with pBK-lib and Mj tRNAtyrCUA and grown in the presence of 1mM 
unnatural amino (UAA) acid and chloroamphenicol. These positively selected plasmids 
are then transformed into negative ones containing Mj tRNAtyrCUA and the toxic barnase 
protein gene with three amber mutations introduced at permissive sites. The cells are 
grown in the absence of UAA, so those possessing any synthetase that aminoacylates 
with an endogenous amino acid will die. Three positive and two negative selections 
generated a mutant of Mj TyrRS, CouRS-D8, with the following mutations Tyr32Glu, 
Leu65His, Ala67Gly, His70Gly, Phe108Tyr, Gln109His, Asp158Gly, and Leu162Gly. 
The presence of four glycines ensure accommodation of 1, and the mutation of Tyr32 and 
Asp158, which hydrogen bonded with tyrosine, is consistent with the lost of activity 
towards tyrosine. The fidelity and efficiency of CouRS-D8 were tested by the Schultz lab 
using sperm whale myoglobin that contained an amber codon at Ser-4 and a C-terminal 
His6 tag. A full-length protein was expressed in minimum media or 2YT in the presence 
of 1mM 1 (Figure 1.7c).  
 
Time-resolved small-angle X-ray scattering as a tool to monitor allosteric transition 
of ATCase. 
X-ray crystallography has provided extremely valuable information in the studies 
of protein function and structure. However, it is limited by the ability of the sample to 
form crystalline solids, which can become a difficulty when the substance to be analyzed 
 21 
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O
H2N
(S)-2-amino-4-(7-hydroxy-2-oxo-2H-chromen-4-
yl)butanoic acid
OO OH
Chemical Formula: C13H13NO5
Molecular Weight: 263.25
m/z: 263.08 (100.0%), 264.08 (14.6%), 265.08 
(1.1%) B  
C  
 
Figure 1.7. A) L-(7-hydroxycoumarin-4-yl) ethylglycine   or (S)-2-amino-4-(7-hydroxy-
2-oxo-2H-chromen-4-yl)butanoic acid (IUPAC naming system) 1. B) Absorption and 
emission spectra of 1. Both spectra were recorded at pH 7.4, 100 mM sodium phosphate 
buffer. At this pH, 1 is present in both phenol and phenolate forms (in approximately a 
2:1 ratio, pKa 7.8). The phenolate form has an extinction coefficient of 17,000 at 360 nm 
and a quantum yield of 0.63.73 C) Coomassie-stained SDS-PAGE (left) of TAG4 mutant 
myoglobin (indicated by black arrow) expression in the presence and absence of 1 mM 1. 
The right panel shows the fluorescence image of wild-type and TAG4 mutant 
myoglobin.73 
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doesn’t crystallize, which is true for many biological species, or when the system needs 
to be studied under the physiological conditions. For these cases, small angle X-ray 
scattering (SAXS), in which radiation is elastically scattered by a sample, is a more 
useful technique since its resulting pattern provides information about size, shape and 
orientation of a certain component of the sample.74,75 SAXS provides low-resolution of  
the sample despite random orientation in solution or its partial order. It allows for time-
resolved studies, which follow the response of a biological system to physical or 
chemical perturbations in the environment. For example, it follows the structural changes 
induced by ligand binding, rapid dilution, pH-jump, etc. This technique’s data can be 
interpreted as is or using high-resolution structures derived from other techniques.  
 Time-resolved small angle X-ray scattering (TR-SAXS) has been used to monitor 
conformational changes of the quaternary structure of E. coli ATCase mixed with 
substrates, substrates analogs, and nucleotide effectors at temperature 5-22º C.76 TR-
SAXS studies during stopped-flow experiments of ATCase showed that the substrate 
binding induces a very quick change from T to R state, and back to T when the substrate 
was exhausted (Figure 1.8a).  TR-SAXS has also given insights into the effect of 
allosteric effectors on the allosteric transition (Figure 1.8b), as well as it has allowed to 
measure the activation energy from T to R state and R to T state. In the presence of ATP, 
an allosteric activator, the enzyme stays a shorter time in the R state due to the quicker 
turnover of substrate. In the presence of the allosteric inhibitors CTP and CTP/UTP, the 
enzyme does not remain in the R state for long either as expected. Moreover, it was found 
that when CTP is present the enzyme population mixed with substrates is not fully 
converted to R state. UTP didn’t affect the T to R transition, but when present the R state 
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Figure 1.8. A) Time-resolved X-ray scattering of ATCase. At t=0 the ATCase:CP 
complex (T state) was mixed with Asp.  The increase in integrated intensity signifies the 
conversion of the enzyme into the R state.76 While substrates are present the enzyme 
remains in the R- state.  The reaction rate was slowed by performing the experiment at 
5°C. B) Time evolution of the ATCase structural change in the presence of allosteric 
effectors at 5°C. Scattering Intensities were integrated over the s range 0.012-0.024 Å-1. 
No effectors (red, square), ATP (blue, circles), CTP (diamond, green), UTP (triangle, 
black).76 
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was shorter than that observed for the enzyme in the absence of nucleotides, which 
suggests some R state destabilization by UTP. These results could have not been obtained 
under steady-state conditions or under other condition than in solution. 
  
Research Scope 
 The main goal of this investigation is to monitor cooperativity and allosteric 
effector binding to ATCase. Large quaternary conformational changes can be monitored 
by X-ray scattering; however, more localized changes are more difficult to study; for 
example, nucleotide binding and effects. ATCase’s regulatory dimer is composed of two 
chains and nucleotides bind with different affinity to each chain. In the case of CTP, it 
has been proposed that when the first CTP molecule binds to one of the chains, this 
causes conformational modifications in the other regulatory chain that diminish the 
binding affinity of the next CTP molecule.52,77 However, in the case of UTP, which is 
only an inhibitor in the presence of CTP, the binding of a CTP molecule to one regulatory 
chain enhances the binding of UTP in the other.77 This research proposes the 
incorporation of a fluorescent amino acid to study the signal transduction process 
involved the negative cooperativity observed in the binding of allosteric effectors to 
ATCase.52, 78-81 
 Chapter 2 focuses on the synthesis and incorporation of the non-commercially 
available L-(7-hydroxycoumarin-4-yl) ethylglycine or (S)-2-amino-4-(7-hydroxy-2-oxo-
2H-chromen-4-yl)butanoic acid (IUPAC naming system) into ATCase using the 
methodology73 outlined by the Schultz Lab, including their plasmids pBKCouRS-D8 and 
pBAD/JYAMP-4TAG-Myo. The selection of appropriate locations for the insertion of 
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the fluorescent amino acid was accomplished with the use of sequence alignments, to 
prevent mutation of conserved residues, and the application of molecular modeling and 
energy minimization software such as NAMD. Finally, the fluorescent ATCases were 
tested to ensure that its kinetics properties are not affected by the unnatural amino acid 
before it was subjected to fluorescent studies. 
 Furthermore, the results obtained for the homotropic interactions of ATCase using 
TR-SAXS will be continued. Due to upgrades to the beamline (BL4-2), previously used, 
to a higher flux and to a new detector, data could be collected at higher resolution and 
better transfer rates. Another advantage of the upgraded system is the use of less amount 
of enzyme. Moreover, the resolution issue caused by the dead time of the stopped-flow 
mixer, which prevents the observation of transiently stable intermediates of ATCase 
formed during the T to R transition, is going to be addressed with the photolysis of a 
caged version of Asp to initiate the T to R transition. Chapter 3 details the synthesis of 4-
methoxy-7-nitroindolinyl-L-aspartate, which is a potential candidate for the described 
time-resolved experiments. The use of this caged Asp combined with the upgrades to 
beamline (BL4-2) might mean in 10-fold increase in time resolution. 
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Results and Discussion 
 ATCase is metabolically regulated both by ATP and CTP, the former as an 
activator, and the latter as an inhibitor. The presence of CTP is also known to increase the 
inhibitory profile of UTP, an otherwise weak inhibitor. Due to the different affinity 
observed for each allosteric site in the regulatory dimer, it has been proposed that the 
binding of CTP to one regulatory chain signals conformational changes in the adjacent 
chain that result in a diminished affinity for CTP, but enhanced affinity for UTP. Thus, 
the signal transmission process involved in the negative cooperativity displayed by the 
binding of these allosteric effectors to ATCase is not yet fully understood. A fluorescent 
probe in ATCase allows for monitoring of nucleotide binding in solution. The fluorescent 
intensity should correlate with the local alterations due to the biomolecular interactions. 
Schultz’s method to incorporate an unnatural fluorescent amino acid in vivo has been 
proven to be a useful and easily applicable technique.  
 
Synthesis of L-(7-hydroxycoumarin-4-yl) ethylglycine 1 
The 7-hydrocoumarin moiety is a well-studied and useful fluorescent probe, 
originally investigated for its high quantum fluorescent yield, relatively large Stoke’s 
shift, small size, and sensitivity to pH and solvent polarity.1 The hydroxycoumarin amino 
acid was synthesized from commercially available Z-Glu-Obzl 2 using a slightly 
modified version (Figure 2.1) of the literature procedures.2,3 The side chain of 2 was 
extended to form a β-ketoester after the treatment with 1,1’-carbonyldiimidazole and 
ethyl magnesium malonate4 to afford a 44% yield. The hydroxycoumarin moiety was 
synthesized, in 50% yield, via a von Pechmann reaction, which involves a phenol  
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Figure 2.1. Scheme for the synthesis of 1. a) 1,1-carbonyldiimidazole (1.1 eq.), 
anhydrous THF, rt, 2h. Then, Ethyl magnesium malonate (0.55 eq), rt, overnight. 44% 
yield. b) resorcinol (5 eq.), methanesulfonic acid (99.9%), rt, 2h. 50% yield. 
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condensation with the β-ketoester in the presence of a variety of acids,5,6 in this case, 
methanesulfonic acid (Brφnsted acid).7  
Figure 2.2A shows a 1H NMR spectrum consistent with the structure of 
compound 3. The ester methyl group is shown as a 3H triplet at δ 1.234 (JH2=7.1 Hz) 
while the ester methylene is a 2H quartet at δ 4.144 (JH2=7.2 Hz). The α-proton to the 
ester carbonyl is a 2H singlet at δ 3.342. The α-proton to the amino acid carbonyl group 
is shown as a 1H multiplet at δ 4.356-4.408. The 1H multiplet between δ 1.901-1.973 
represents one of the β-methylene, non-equivalent protons in the side chain, while the 
other, also a multiplet, is at δ 2.157-2.205. The side-chain γ-protons are shown as a 2H 
multiplet at δ 2.484-2.619. The two 2H singlets at δ 5.077 and 5.144 correspond to the 
methylene protons of the benzyl protecting groups. Lastly, the 1H doublet at δ 5.410 
(JH2=8.0 Hz), and the 10H singlet at δ 7.26-7.328 represent the amine and the two phenyl 
rings, respectively. 
The 13C NMR spectrum of 2, given in figure 2.2B, shows the methyl of the ethyl 
ester group at δ 14.12 and the methylene at δ 61.38. C-3, C-4, C-6 and C-2 are at 26.16, 
38.62, 49.16, and 53.26, respectively. The two methylenes from the benzyl groups are 
shown at δ 67.02 and δ 67.30. Signals at δ 128.04, 128.13, 128.29, 129.47, 128.59, 
135.18, and 136.18 are consistent with the carbons of the phenyl ring. The C-1 carbonyl 
is shown at δ 171.68 and the carbonyl of the benzyloxycarbonylamino group is at δ 
155.99. C-5 and C-7 carbonyls of the β-keto ester are at δ 166.91 and 201.47. 
The final fluorescent amino acid was fully characterized using NMR spectroscopy 
and mass spectroscopy. The 1H NMR spectrum is given in Figure 2.3A and shows the γ-  
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Figure 2.2 A) 1H-NMR spectrum of (S)-1-benzyl 7-ethyl 2-(benzyloxycarbonylamino)-5-
oxoheptanedioate. B) 13C-NMR spectrum of (S)-1-benzyl 7-ethyl 2-
(benzyloxycarbonylamino)-5-oxoheptanedioate 
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Figure 2.3. A) 1H-NMR spectrum of L-(7-hydroxycoumarin-4-yl) ethylglycine. B) 13C-
NMR spectrum of L-(7-hydroxycoumarin-4-yl) ethylglycine 
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A  
B  
Figure 2.4. A) Isotope model B) HMQC spectrum of L-(7-hydroxycoumarin-4-yl) 
ethylglycine. 
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protons to the amino acid carbonyl group as a 2H multiplet at δ 1.89-1.94, the β-protons 
as a multiplet at δ 2.43-2.54 and the α-proton as a triplet at δ 3.88 (J H2=6.2 Hz). The 1H 
singlet at δ 5.77 corresponds to the proton at C-3 in the coumarin moiety, while the 1H 
singlet at δ 6.11 belongs to the proton at C-8. The 1H doublet at δ 6.40 (JH2=8.8 Hz) and 
the one at δ 7.03  (JH2=8.0 Hz) correspond to the protons at C-5 and C-6 of the coumarin 
ring system, respectively.  
Figure 2.3B shows the 13C NMR C-3, C-4, and C-2 at δ 27.45, 29.27, and 52.19, 
respectively. Signals at δ 103.13, 110.23, 111.43, 113.62, and 126.76 correspond to C-8, 
C-3, C-4a, C-6, and C-5 of the hydroxycoumarin moiety. The quarternary C-4 and C-1a 
are shown at δ 155.68 and 160.81. The C-2 carbonyl of the coumarin ring is at δ 161.88 
and the carbonyl C-1 is at δ 171.15. Figure 2.4A shows an ESI-MS m/z isotope model 
predicted and observed of 1, and Figure 2.4B presents a region of the HMQC spectrum of 
L-(7-hydroxycoumarin-4-yl) ethylglycine. 
 
Expression of E52Z and L58Z mutants of ATCase 
The E52Z, L58Z, and E52Z R-chain mutants of ATCase, were successfully 
overexpressed in E. coli using the plasmids pEK684, pEK685, and pEK692, respectively, 
cotransformed with pBKCouRS-D8 in Top10 cells. Because of the introduction of the 
nonsense codon, the general protein expression protocol for these mutants was, therefore, 
carried out in the presence of Mj tRNAtyrCUA and the Schultz’s selected synthetase Mj 
TyrRS in glycerol minimum media, supplemented with 1.5 mM of 1 to afford ~36 mg/L 
for E52Z holo and E52Z R chain, and ~3 mg/L of L58Z holo (Figure 2.5).  
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A         B 
 
 
 
 
     C 
Figure 2.5. A) Black and white image* of a coomassie-stained SDS-PAGE (right) and 
fluorescent imageO of an unstained SDS-PAGE (left) of E52Z. B) Black and white 
image* of a coomassie-stained nondenaturing-PAGE (right) and fluorescent image of an 
unstained nondenaturing-PAGE (left) L58Z. C) Black and white image* of a coomassie-
stained SDS-PAGE (top) and fluorescent image of an unstained SDS-PAGE (bottom) 
E52Z R only. 
*Taken with a Stratagene EagleEye High Performance. 
OTaken with a digital camera on a photdyne transiluminator at 344nm. 
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Figure 2.6. Aspartate saturation curves E52Z () and L58Z () ATCase holoenzymes. 
Specific activity is reported in millimoles of N-carbamoyl-L-aspartate formed per h per 
mg of protein. Conditions of the assays were 25° C and pH 8.3, with saturating 
concentrations of carbamoyl phosphate in 50 mM Tris-acetate buffer. Data shown are 
from individual assays that resemble the observed averages. 
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Table 2.1. Kinetic parameters for wild-type and mutant holoenzymes  
Holoenzyme Vmax [Asp]0.5 nH 
 mmol h-1 mg-1 mM  
Wild-type7 19.7 ± 0.6 13.6 ± 0.3 2.6 ± 0.2 
E52Z 13.1 ± 0.05 12.8 ± 0.07 2.5  
L58Z 12.2 ± 0.03 6.21  1.4 ± 0.1 
Data were determined from the aspartate saturation curves (Figures 2.6), and are an 
average of two independent assays. Colorimetric assays were performed at 25° C, in 50 
mM Tris-acetate buffer, pH 8.3, and at saturating levels of carbamoyl phosphate for 
varying aspartate curves. 
Table 2.2. CTP inhibition and ATP activation of the wild-type and mutant holoenzymes 
CTP ATP     
Enzyme Residual 
Activity 
K Activation K 
 % mM % mM 
Wild-type7 26.9 ± 1.7 0.090 ± 0.001 378 ± 11 2.2 ± 0.03 
E52Z 41.9 ± 0.1 0.079 ± 0.002 289.8 ± 9.1 1.15 ± 0.14 
L58Z 79.4 ± 0.1 0.71 ± 0.01 112.7 ± 10 0.98 ±0.1 
The data were determined from the ATP and CTP saturation curves (Figure 2.7), and are 
the average of two independent determinations. Colorimetric assays were performed at 
25° C, in 50 mM Tris-acetate buffer, pH 8.3, and at aspartate concentrations of one-half 
the [Asp]0.5 of the respective holoenzyme, and saturating levels of carbamoyl phosphate. 
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Steady-State Kinetics 
The aspartate saturation curves for the wild-type and mutant holoenzymes can be 
found in Figure 2.6, and their corresponding kinetic data are summarized in Table 2.1. 
The E52Z enzyme has a similar [Asp]0.5 and Hill coefficient comparing to the wild-type 
enzyme, implying that the binding of aspartate and the homotropic cooperativity of the 
enzyme were unaffected by this mutation. In the case of L58Z, the [Asp]0.5 was reduced 
two-fold, which suggests higher binding affinity of aspartate. It also presents a two-fold 
reduced Hill coefficient; however, this value is still larger than 1, indicating that the 
mutant still has positive homotropic cooperativity. Moreover, compared to the wild-type 
enzyme, the maximal observed velocities for the E52Z and L58Z enzymes are reduced by 
approximately 1.5-fold and 1.6-fold, respectively.  
As far as the observed values, both ATCase mutants displayed kinetics properties 
similar to the wild-type enzyme, therefore assuring that the basic enzymatic function 
which allowed the use of these mutant enzymes for the fluorescent studies proposed was 
preserved. 
 
Influence of allosteric effectors 
The heterotropic effects of ATP and CTP were kinetically determined for the 
mutant enzymes (Figure 2.7 and Table 2.2). The nucleotide effects were determined at an 
aspartate concentration of one half the [Asp]0.5, because nucleotides influence the enzyme 
to a greater extent as the aspartate concentration is reduced.8 ATP activates, while CTP 
inhibits the  E52Z and L58Z ATCases. The E52Z ATCase displays a 1.3-fold decrease in 
maximal activation by ATP and a 1.6-fold decrease in the maximal inhibition by CTP 
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compared to wild-type. The L58Z reveals an even lower maximal inhibition by CTP, 
decreased three-fold with respect to wild-type ATCase. Moreover, It was observed a 3.4-
fold decrease in maximal inhibition by CTP in L58Z ATCase compared to wild-type 
enzyme.   
Even though the activation by ATP and inhibition by CTP observed are slightly 
different from the values displayed by wild-type enzyme, both mutants are still affected 
by the binding of these allosteric effectors. Therefore, the E52Z and L58Z enzymes 
present close to normal activity, which is necessary for an appropriate characterization of 
their fluorescence by steady-state measurements. Moreover, it is important to note that 
the binding isotherms of ATP and CTP are slightly affected due to the fact that the 
hydroxycoumarin amino acid was positioned in close proximity to the allosteric pocket.  
 
Fluorescent Steady-State Studies 
 In order to study the allosteric control and cooperativity of nucleotides in 
ATCase, fluorescent measurements were carried out using E52Z R-chain, E52Z 
holoenzyme, and L58Z holoenzyme fluorescent mutants (Figures 2.1 - 2.17 and Tables 
2.3 - 2.6) at 25º C, while varying the nucleotide concentration, as well as, pH. The 
standard pH for ATCase holoenzyme measurements and assays is 8.3 because ATCase’s 
highest activity is observed under these conditions. Measurements were also performed at 
pH 7 due to literature9 suggesting a stronger effect of the nucleotides on ATCase under 
these conditions.  Fluorescent measurements were carried out in the presence and in the 
absence of the ATCase ligand CP, in order to distinguish effects due to nucleotide 
binding to the active site from binding to the allosteric sites. In Figures 2.8 and 2.9, the  
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Figure 2.7. Effects of varying ATP (B) and CTP (A) in E52Z () and L58Z () ATCase 
holoenzymes. The colorimetric assays were preformed at 25° C and pH 8.3 in 50mM 
Tris-acetate buffer with saturating concentrations of carbamoyl phosphate and 
concentrations of aspartate held constant at one-half of the [Asp]0.5. Data shown are from 
individual assays that resemble the observed averages. 
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Figure 2.8. Effects of varying CTP (A) and ATP (B) in the fluorescent measurements of 
E52Z R Chain. The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-
acetate buffer. 
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Figure 2.9. Effects of varying UTP (A) and UTP with a saturating concentration of CTP 
(2mM) (B) in the fluorescent measurements of E52Z R chain. The measurements were 
preformed at 25° C and pH 8.3 in 50mM Tris-acetate buffer. 
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Figure 2.10. Effects of varying CTP (A) and ATP (B) in the fluorescent measurements of 
E52Z ATCase holoenzyme. The measurements were preformed at 25° C and pH 7.0 in 
50mM Tris-acetate buffer. 
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Figure 2.11. Effects of varying UTP (A) and UTP with a saturating concentration of CTP 
(2mM) (B) in the fluorescent measurements of E52Z ATCase holoenzyme. The 
measurements were preformed at 25° C and pH 8.3 in 50mM Tris-acetate buffer. 
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Figure 2.12. Effects of varying CTP the fluorescent measurements of E52Z ATCase 
holoenzyme. (A) The measurements were preformed at 25° C and pH 7 in 10mM HEPES 
buffer with saturating concentrations of carbamoyl phosphate () or in its absence (). 
(B) The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-acetate buffer 
with saturating concentrations of carbamoyl phosphate () or in its absence ().  
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Figure 2.13. Effects of varying ATP in the fluorescent measurements of E52Z ATCase 
holoenzyme. (A) The measurements were preformed at 25° C and pH 7 in 10mM HEPES 
buffer with saturating concentrations of carbamoyl phosphate () or in its absence (). 
(B) The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-acetate buffer 
with saturating concentrations of carbamoyl phosphate () or in its absence (). 
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Figure 2.14. Effects of varying UTP in the fluorescent measurements of E52Z ATCase 
holoenzyme. The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-
acetate buffer with saturating concentrations of CP and CTP () or in its absence of CTP 
().  
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Figure 2.15. Alterations in the fluorescent of the L58Z ATCase holoenzyme with 
variation of CTP. (A) The measurements were preformed at 25° C and pH 7 in 10mM 
HEPES buffer with saturating concentrations of carbamoyl phosphate () or in its 
absence (). (B) The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-
acetate buffer with saturating concentrations of carbamoyl phosphate () or in its 
absence ().  
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Figure 2.16. Alterations in the fluorescent of the L58Z ATCase holoenzyme with 
variation  of ATP. (A) The measurements were preformed at 25° C and pH 7 in 10mM 
HEPES buffer with saturating concentrations of carbamoyl phosphate () or in its 
absence (). (B) The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-
acetate buffer with saturating concentrations of carbamoyl phosphate () or in its 
absence (). 
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Figure 2.17. Alterations in the fluorescent of the L58Z ATCase holoenzyme with 
variation  of UTP. (A) The measurements were preformed at 25° C and pH 8.3 in 50mM 
Tris-acetate buffer with saturating concentrations of carbamoyl phosphate () or in its 
absence (). (B) The measurements were preformed at 25° C and pH 8.3 in 50mM Tris-
acetate buffer with saturating concentrations of carbamoyl phosphate () or in its 
absence () and saturating concentration of CTP (2mM). 
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Table. 2.3. CTP binding 
Enzyme Buffer Additional 
ligand 
[CTP] 
range 
K1 K2 
  mM mM mM mM 
E52Z-R  Tris pH 8.3  0 – 10 6.1 0.09 
E52Z-holo Tris pH 7  0 - 15 5.0 0.008 
E52Z-holo Hepes pH 7  0 - 15 0.10 ± 0.02  ND 
E52Z-holo Hepes pH 7 CP, 4.8mM 0 - 15 0.46 ± 0.02 ND 
E52Z-holo Tris pH 8.3  0 - 15 ND 5.5 
E52Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 ND 10 
L58Z-holo Hepes pH 7  0 - 15 ND ND 
L58Z-holo Hepes pH 7 CP, 4.8mM 0 - 15 ND ND 
L58Z-holo Tris pH 8.3  0 - 15 0.012 ± 0.005 1.0 ± 0.09 
L58Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 0.0052± 0.0075 1.5 ± 0.22 
The data were determined from the CTP saturation curves (Figure 2.8A, 2.10A, 2.12, and 
2.15), and represent one determination for each fluorescent steady-state study. 
ND= not determined 
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Table. 2.4. ATP binding 
Enzyme Buffer Additional 
ligand 
[ATP] 
range 
K1 K2 
  mM mM mM mM 
E52Z-R  Tris pH 8.3  0 – 15 5.7 0.11 
E52Z-holo Tris pH 7  0 - 15 3.5 ND 
E52Z-holo Hepes pH 7  0 - 15 ND ND 
E52Z-holo Hepes pH 7 CP, 4.8mM 0 - 15 ND ND 
E52Z-holo Tris pH 8.3  0 - 15 0.04 2.7 
E52Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 0.04 2.61 
L58Z-holo Hepes pH 7  0 - 15 1.95 ND 
L58Z-holo Hepes pH 7 CP, 4.8mM 0 - 15 0.39 ± 0.06 ND 
L58Z-holo Tris pH 8.3  0 - 15 0.056 ± 0.0022 0.58 ± 0.08 
L58Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 0.063 ± 0.0019 0.61 ± 0.071 
The data were determined from the ATP saturation curves (Figure 2.8B, 2.10B, 2.13, 
and 2.16), and represent one determination for each fluorescent steady-state study. 
ND= not determined 
 
 
 
 
 
 63 
 
Table. 2.5. UTP binding 
Enzyme Buffer Additional 
ligand 
[UTP] 
range 
K1 K2 
  mM mM mM mM 
E52Z-R  Tris pH 8.3  0 - 15 0.009 3 
E52Z-holo Tris pH 7  0 - 15 0.02 2.2 
E52Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 2.1 ND 
L58Z-holo Tris pH 8.3  0 - 15 ND ND 
L58Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 ND ND 
The data were determined from the UTP saturation curves (Figure 2.9A, 2.11A, 2.14, 
and 2.17A), and represent one determination for each fluorescent steady-state study. 
ND= not determined 
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Table. 2.6. UTP/CTP binding 
Enzyme Buffer Additional 
ligand 
[UTP] 
range 
K1 K2 
  mM mM mM mM 
E52Z-R  Tris pH 8.3  0 – 10 0.009 3 
E52Z-holo Tris pH 7  0 - 15 0.0045 9 
E52Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 1.22 ND 
L58Z-holo Tris pH 8.3  0 - 15 ND ND 
L58Z-holo Tris pH 8.3 CP, 4.8mM 0 - 15 ND ND 
The data were determined from the UTP saturation curves (Figure 2.9B, 2.11B, 2.14, 
and 2.17B), and represent one determination for each fluorescent steady-state study. 
ND= not determined 
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emission intensity was normalized by the highest value. The emission intensities of 
Figures 2.10 and 2.11 were divided by 155 µg/mL, which corresponds to the amount of 
E52Z holoenzyme present. In Figures 2.12 - 2.14, the emission was divided by 210 
µg/mL. Lastly, the emission observed in Figures 2.15 - 2.17 for the L58Z holoenzyme 
was divided by 36 µg/mL. 
The most valuable observations during the fluorescent measurements are changes 
in the fluorescent intensity, which prove the sensitivity of the 7-hydrocoumarin amino 
acid at the selected positions to the binding of nucleotides. Fluorescent experiments on 
the E52Z regulatory chain (Figures 2.8 and 2.9, Tables 2.3-2.6) show, with all 
nucleotides, a dramatic exponential decline in emission with each NTP concentration 
between 0 - 1 mM, and a much more gradual drop that occurs after 1 mM to the point of 
saturation at 15 mM. This observation might be tied to the higher affinity10 of allosteric 
effectors to three of the six binding sites available.11, 12 Since the complexity of the 
binding isotherms is due to the nucleotides’ interactions, not only with the regulatory 
chain but also with the catalytic subunit,13 fluorescent measurement of the active E52Z 
regulatory subunit at varying NTP concentration simplified the observed interactions.  
The first experiments performed on the E52Z holoenzyme were done at pH 7 in 
50 mM Tris buffer (Figures 2.10 and 2.11, Tables 2.3 - 2.6). The results observed for 
emission changes are similar to those for the E52Z R chain’s experiments, consisting of a 
dramatic exponential decline followed by a gradual change. However, it was determined 
that these results are not a good representation of the interaction of the fluorescent E52Z 
ATCase with the NTPs. First, it is important to mention that the 50 mM Tris solution is 
not a buffer at pH 7. It was also noted that the NTP stock solutions were not neutralized 
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before the experiments; moreover, the 7-hydrocoumarin amino acid fluorescence is 
sensitive to solvent polarity. Taking these factors into consideration, it was determined 
that the changes in emission are mainly due to changes in media polarity affecting the 
enzyme folding rather than pure interactions of the enzyme with the nucleotides. These 
mistakes were corrected in the following fluorescent experiments repeated for E52Z 
holoenzyme, and consequently for L58Z holoenzyme, using 10 mM Hepes at pH 7 and 
50 mM Tris at pH 8.3.   
E52Z holoenzyme experiments at pH 8.3 (Figures 2.12B, 2.13B, and 2.14B) were 
analyzed by curve fitting procedures (Tables 2.3 - 2.6). The enzyme behaves in a similar 
manner in the presence or absence of CP as an active site ligand for all nucleotides. The 
emission intensity plotted from the highest point observed in the fluorescent 
measurements also resembles the observations in the R chain measurements. However, 
experiments at pH 7 displayed a very different pattern of behavior. In the case of CTP 
heterotropic interactions (Figure 2.12A), the emission changes observed in the presence 
and the absence of CP are inverse to each other and could not be analyzed by curve 
fitting procedures. ATP effects at pH 7 (Figure 2.13A) could not be fitted, but the 
measurements in the presence and absence of CP showed similar emission changes, 
consisting of an abrupt decline between ATP concentrations of 0 and 0.1 mM, followed 
by a steady increase up to 7 mM, where a plateau was reached.  
Emission changes due to CTP interactions with the L58Z holoenzyme (Figure 
2.15B, Table 2.3) at pH 8.3 are equivalent to the behavior observed in E52Z holoenzyme. 
Fluorescent measurements in the presence of ATP at pH 8.3 with L58Z holoenzyme 
(Figure 2.16B) show a steady decline in emission in the presence and absence of CP, 
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rather than the usual steep decline followed by a moderate change. It was also analyzed 
by curve fitting procedures (Table 2.4). In the case of varying concentration of UTP in 
the presence and absence of a saturating concentration of CTP (Figure 2.17), the changes 
in emission are inverse.  UTP causes the fluorescence to increase precipitously between 0 
and 1 mM, and then to decrease steadily to saturation at 15 mM. UTP in the presence of 
CTP (2 mM) interacts by decreasing the emission abruptly, followed by a gradual 
increase. L58Z holoenzyme interactions with CTP in the presence and absence of CP at 
pH 7 (Figure 2.15A) cause a similar behavior to that observed for E52Z holoenzyme 
without CP, which consists of a sharp increase in emission between 0 and 1 mM CTP, 
followed by a steady decline. Finally, ATP interacted with L58Z holoenzyme at pH 7 
(Figure 2.16A) in the presence and absence of CP by sharply increasing the emission 
intensity between concentrations of 0 to 1 mM. These ATP fluorescent measurements 
were analyzed by curve fitting procedures (Table 2.4). 
These preliminary results should be repeated and complemented by fluorescent 
lifetime measurements in order to provide a complete picture of the behavior of these 
mutant enzymes in the presence of the various nucleotides, as well as more defined 
interpretations for the data observed. 
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Chapter 3. Synthesis of Caged Aspartate for time-
resolved small-angle x-ray scattering of ATCase 
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Results and Discussion 
Time-resolved small-angle X-ray scattering has been used to monitor the T to R 
state transition in ATCase, to observe the enzyme catalysis in the R state, and to detect 
ATCase’s relaxation back to the T state once the substrates have been exhausted. Further 
studies need to be accomplished using TR-SAXS to probe homotropic cooperativity, as 
well as to understand the signal transduction events caused by the heterotropic 
interactions. However, the resolution of TR-SAXS in the study of heterotropic 
interactions and homotropic cooperativity of ATCase is limited by the dead time of the 
stopped-flow mixer; therefore, the photolysis of caged substrates would allow access to 
faster time resolution. 
Synthesis of (S)-2-amino-4-(4-methoxy-7-nitroindolin-1-yl)-4-oxobutanoic acid  
Among caged compounds for biological studies, 1-acyl-7-nitroindolines have 
been described as promising reagents for rapid photolytic generation of glutamate,1 and 
therefore of others amino acids as well. 1-acyl-5-methoxycarbonylmethyl-7-nitroindolyl 
derivatives have been subjected to photohydrolysis in aqueous solution to afford a 
carboxylic acid and the 5-subtituted-7-nitroindole without incorporation of water into the 
products.1 The efficiency in single-flash experiments depends on a combination of the 
absorption coefficient at the wavelength of the irradiating light and the product quantum 
yield. Furthermore, a more recent study2 focused on enhancing this absorption coefficient 
by introducing an electron-donating substituent, such as a methoxy group, para to the 
nitro group. At the end of this investigation, it was also discovered that the positive effect 
of the electron-releasing group at C-4 on photolysis efficiency is greater without 
substitution at C-5; thus, 4-methoxy-7-nitroindoline moiety was found to be the most 
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Figure 3.1. A) Scheme for the synthesis of 7. a) Cyanoborohydride (1 N in anhydrous 
THF), acetic acid , 12 ºC - rt, overnight., then adjust pH 14. 100% conversion. b) 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide (1.4 eq), DMAP (3 eq), anhydrous 
acetonitrile, rt. Then, Boc-Asp-OtBu (1.2 eq), anhydrous acetonitrile, r.t., overnight. 70% 
yield. d) sodium nitrate (1 eq), TFA, -15 ºC, 1h. Then, adjust pH to 6.7. 15% yield. 
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efficient cage for glutamate.2 The measured amount of glutamate in the photolysed 
solution was between 88% and 93% of what was expected, considering the amount of 
consumed starting material, and the product quantum yield was 0.085 at 347 nm. Other 
studies involving a caged-D-aspartate derivative presented a quantum yield of 0.09.3 This 
compound was also found to be stable for 24 h in physiological conditions.4 Based on 
these results the L-aspartate derivative of 4-methoxy-7-nitroindoline was synthesized. As 
shown on figure 3.1A, the 4-methoxyindole 4 was reduced to the indoline 5 in 100% 
yield by using a literature procedure.4 Figure 3.2A shows the MS ESI m/z spectrum of 4-
methoxyindoline, while Figure 3.2B is the 1H NMR spectrum. Protons on C-2 are shown 
at δ 2.99 as 2H triplet (JH2=8.4 Hz) and protons on C-3 are also a 2H triplet at δ 3.55 (J 
H2=8.4 Hz). The methyl protons of the methoxy group are a 3H singlet at δ 3.80. Protons 
on C-5 and C-7 are shown as a 2H quartet at δ 6.30 (J H2=8.2 Hz, 2 Hz) and the proton on 
C-6 is a 1H triplet at δ 6.99 (J H2=8.0 Hz,). 
 Acylation of 4-methoxyindoline with Boc-Asp-OtBu from slightly modified 
literature procedures2,3,4 involving 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 
DMAP as coupling reagents afforded compound 6 in 70% yield, after flash 
chromatography (Figure 3.1B). Figure 3.3A shows a 1H NMR spectrum consistent with 
(S)-tert-butyl 2-(tert-butoxycarbonylamino)-4-(4-methoxyindolin-1-yl)-4-oxobutanoate. 
The methyl groups of the BOC and tert-butyl groups are shown as 9H singlets at δ 1.41 
and  1.42. The non-equivalent β-protons are at δ 2.80 as a 1H doublet of doublets  
(JH2=13.2 Hz, 3.6 Hz) and at 3.05-3.14 as a 3H multiplet, which also includes protons on 
C-2 of 4-methoxy-7-niroindoline. The methyl protons of the methoxy group are a 3H 
singlet at δ  3.80. The 2H triplet at δ 4.00 (JH2=8.4 Hz) represents protons on 
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Figure 3.2. A) MS ESI m/z B) 1H NMR spectrum of 4-methoxyindoline. 
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Figure 3.3. A) 1H NMR and B) 13C NMR spectra of Synthesis of (S)-tert-butyl 2-(tert-
butoxycarbonylamino)-4-(4-methoxyindolin-1-yl)-4-oxobutanoate 6 
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C-3 of 4-methoxy-7-nitroindoline. The α-proton of the amino acid chain is a 1H multiplet 
at δ 4.43-4.47 and the amine is a 1H doublet at δ 5.80 (J=8.8 Hz,). Protons on C-5 and C-
7 are 1H doublets at δ 6.55 (J H2=7.6 Hz,) and δ 7.76 (JH2=8.0 Hz), respectively.  The 
proton on C-6 of the indoline moiety is a 1H triplet at δ 7.12 (JH2=8.2 Hz). The 13C NMR 
spectrum of 6 (figure 3.3B) shows 4-methoxy-7-nitroindoline C-3, C-2, C-5, C-7, C3a, C-
6, C-7a, and C-4 at δ 25.26, 50.73, 106.26, 110.07, 118.42, 129.04, 144.06, 155.91, 
respectively. The methyls of the BOC and tert-butyl protecting groups are at δ 28.08 and 
28.54, while the methynes are at δ 79.66 and 81.98. The β-carbon of the amino acid side 
chain is at δ 38.49 and the α-carbon is at δ 48.55. The methyl of the methoxy group is at 
δ 55.47. The BOC carbonyl carbon is at δ 155.83, the amino acid side chain carbonyl 
carbon is at δ 168.57, and the amino acid carbonyl carbon is δ 170.56. 
The nitro functionality was introduced by treating 6 with sodium nitrate in TFA. 
These conditions also removed the BOC and tert-butyl protecting groups to afford the 
photolabile caged-L-asparate and the photostable 4-methoxy-5-nitroindoline derivative. 
(S)-2-amino-4-(4-methoxy-7-nitroindolin-1-yl)-4-oxobutanoic acid 7 was obtained in 15% 
yield after elution with 24% acetonitrile and 0.1% TFA in water during HPLC purification. 
The final product was characterized by NMR and MS spectroscopy. The 1H NMR 
spectrum in figure 3.4A shows a singlet at δ 2.79 that corresponds to DMSO, which was 
used as standard for the 13C NMR. The 2H triplets at δ 3.02 (JH2=8.0 Hz) and 4.24 
(JH2=8.0 Hz) represent protons on C-3 and C-2 of the 4-methoxy-7-nitroindoline moiety, 
respectively. The β-protons on the amino acid side chain are shown as 2H doublets of 
doublets at δ 3.30 and 3.38  (JH2=5.6 Hz, 1.8 Hz and JH2=4.4 Hz, 1.8 Hz), and the  
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Figure 3.4. A) 1H NMR and B) 13C NMR spectra of Synthesis of Synthesis of (S)-2-
amino-4-(4-methoxy-7-nitroindolin-1-yl)-4-oxobutanoic acid 7 
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α-proton is a 1H triplet at δ 4.37 (JH2=5.0 Hz). The methyl protons of the methoxy group 
are displayed as a 3H singlet at δ 3.90. Proton on C-5 and the one on C-6 of the 4- 
methoxy-7-nitroindoline moiety are 1H doublets at δ 6.80 (JH2=8.8 Hz) and 7.58 (JH2=9.2 
Hz), respectively. Moreover, the protons on C-6 and C-7 of the 4-methoxy-5-
nitroindoline derivative were also observed as 1H doublets, but between δ 7.6 and 7.8. 
Figure 3.4B displays the 13C NMR spectrum of 7. 4- methoxy-7nitroindoline moiety C-3, 
C-2, C-5, C-3a, C-6, C-7, C-7a, and C-4 are observed at δ 25.93, 49.79, 108.28, 123.86, 
125.65, 134.30, 135.00, and 159.53, respectively. The β-carbon of the amino acid side 
chain is at δ 34.89 and the  α-carbon is at δ 50.43. The signal at δ 56.32 corresponds to 
the methyl of the methoxy group. The side chain carbonyl is at δ 169.26, while the other 
is observed at δ 171.13. 
Before using the caged-L-aspartate in TR-SAXS measurements, 7 is going to be 
tested by a continuous pH stat assay5 in order to determine that the compound is not a 
substrate or inhibitor for ATCase. Finally, the photolysis of caged-L-aspartate 7 will be 
carried out under the most favorable conditions for ATCase.  
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Materials and Methods 
Materials 
 Agar, L-aspartate ATP, CTP, carbamoyl phosphate dilithium salt, N-carbamoyl-
L-aspartate, 2-mercaptoethanol, potassium dihydrogen phosphate, sodium EDTA, uracil, 
and L-tryptopham, potassium malonate, magnesium chloride, 1,1-carbonyldiimidazole, 
methanesulfonic acid, sodium nitrate, 4-methoxyindole, 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide, DMAP(4-dimethylamino)pyridine, sodium cyanoborohydrate 1.0M in 
tetrahydrofuran, DEAE sephadex A-25, thin-layer chromatography silica plates and 
anhydrous solvents were purchased from Sigma Aldrich (St. Luois, MO). Trifluoroacetic 
acid and resorcinol were obtained from Acros Organics (Morris Plains, NJ). Z-Glu-Obzl 
and Boc-Asp-OtBu were bought from Novabiochem (Gibbstown, NJ). Column 
chromatography silica gel was purchased from AK Scientific, Inc (Mountain View, CA). 
Acetic acid, antipyrine, diacetylmonoxime and organic solvents were obtained from 
Fisher Scientific Chemical Co. (Pittsburgh, PA). Carbamoyl phosphate dilithium salt, was 
purified before use by precipitation from 50% (v/v) ethanol and was stored desiccated at -
20º C. Casamino acids, yeast extract, and tryptone were obtained from Difco (Detroit, 
MI). Enzyme grade ammonium sulfate, Tris, and electrophoresis grade acrylamide were 
from ICN Biomedicals (Costa Mesa, CA). DNA oligonucleotides were purchased from 
Operon Technology (Alameda, CA). The QuikChange site-directed mutagenesis kit was 
obtained from Stratagene (La Jolla, CA). The QIAprep Miniprep kit from Qiagen 
(Valencia, CA) was used for plasmid preparation, and sequencing was performed by 
Genewiz (North Brumswick, NJ). TOP10 cells were obtained from Invitrogen Life 
Technologies (Carlsbad, CA). Q-Sepharose Fast Flow resin and Phenyl Sepharose were 
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obtained from Amersham Biosciences. IMAC Sepharose and Source-Q resins were 
purchased from GE Healthcare (Pittsburgh, PA). 
 
Methods  
Purification: Enzyme purification was performed on a BioLogic Workstation 
using a metal chelating resin or hydrophobic interaction resin. HPLC data were obtained 
from a BioLogic Duo-Flow (Bio-Rad F-10 head pump) using a reversed-phase column 
[Phenomenex Gemini 5u C18 110A (00D-4435-E0)]. UV detection was with a Bio-Rad 
detector at 254 nm. Semi-preparative HPLC was performed on a 250 x 10 mm column 
[Phenomenex Gemini 10u C18 110A (00G-4436-N0)]. HPLC buffer A was composed of 
5% CH3CN, 0.1% TFA (v/v) in water, and buffer B is 95% CH3CN, 0.1% TFA (v/v) in 
water. 
Characterization:  
1H and 13C NMR spectra were recorded on Varian 300 or 400 spectrometers. 
Proton chemical shifts are reported in ppm (δ) relative to internal tetramethylsilane 
(TMS, δ 0.0) or with the solvent reference relative to TMS as the internal standard 
(CDCl3, δ 7.24 ppm; DMSO-d6, δ  2.50 ppm). Data was reported as follows: chemical 
shift (multiplicity [singlet (s), doublet (d), triplet (t), and multiplet (m)], coupling 
constants [Hz], integration), 13C NMR spectra were recorded on a Varian 400 (100MHz) 
with complete proton decoupling. The chemical shifts were reported relative to CDCl3, (δ 
77.0 ppm) and DMSO-d6, (δ  39.52 ppm). Mass spectra were obtained from the Mass 
Spectrometry Facilities of Boston College. 
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Fluorescent measurements:  
Fluorescent emission spectra were recorded at 20 + 1º C on a Jasco FP-6300 
spectrofluorometer. The excitation wavelengths were 330 and 350 nm. The emission 
spectra were collected between 300 and 550 nm. 
 
Synthesis of L-(7-hydroxycoumarin-4-yl) ethylglycine 
Preparation of Ethyl Magnesium Malonate 
To a stirred aqueous solution of 3 M ethyl potassium malonate (ex. 20 mL), was 
added a 1.5 M solution of magnesium chloride  (ex. 20 mL). After stirring for five min, 
five solution volumes of isopropanol were added (ex. 100 mL). The white precipitate was 
filtered off. The filtrate was reduced under vacuum to the original aqueous volume and 
the sample was lyophilized to afford 8.5 g (100%) of product.  
 
Synthesis of (S)-1-benzyl 7-ethyl 2-(benzyloxycarbonylamino)-5-oxoheptanedioate 
To a stirred solution Z-Glu-Obzl (13.45 mmol, 5 g) in anhydrous THF (50 mL) 
under nitrogen, was slowly added solid carbonyldiimidazole (2.6 g, 14.80 mmol, 1.1 eq), 
and the reaction mixture was allowed to stir for two hours. Ethyl magnesium malonate 
(2.3 g , 7.4 mmol, 0.55 eq) was then added to the reaction mixture as a solid, and the 
reaction was stirred overnight at room temperature under nitrogen. THF was removed 
under vacuum. The crude product was dissolved in ethyl acetate and washed with 10% 
sodium bicarbonate solution, water, and brine. The ethyl acetate layer was dried with 
sodium sulfate and the solvent was reduced under vacuum. The residue was subjected to 
flash chromatography on silica gel using 0-50% ethyl acetate in hexane to afford a white 
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solid in 44% yield. 1H NMR (400 MHz, CDCl3): δ 1.234 (t, J=7.1 Hz, 3H), 1.901-1.973 
(m, 1H), 2.157-2.205 (m, 1H), 2.484-2.619 (m, 2H), 3.342 (s, 2H), 4.144 (q, J=7.2 Hz, 
2H), 4.356-4.408 (m, 1H), 5.077 (s, 2H), 5.144 (s, 2H), 5.410 (d, J=8.0 Hz, 1H), 7.26-
7.328 (m, 10H). 13C NMR (100MHz, CDCl3): δ 14.12, 26.16, 38.62, 49.16, 53.26, 61.38, 
67.02, 67.30, 128.04, 128.13, 128.29, 129.47, 128.59, 135.18, 136.18, 155.99, 166.91, 
171.68, 201.47. ESI –MS for C24H27NO7 (M – H+) 440.18. 
 
Synthesis L-(7-hydroxycoumarin-4-yl) ethylglycine 
To 1A (1.5 g, 3.4 mmol) placed into a dry round bottom flask under nitrogen, was 
added resorcinol (1.87 g, 16.9 mmol) dissolved in anhydrous methanesulfonic (10 mL). 
The reaction mixture was allowed to stir for 2 h at room temperature. Diethyl ether (100 
mL) was added to the mix while cooling it to -30º C. The yellow precipitate was filtered 
off, washed with ether and dissolved in water. The solution volume was reduced under 
vacuum to about 20 ml or less and passed through Sephadex A-25 resin, using water as 
mobile phase. Pure, collected product was lyophilized to afford a yellow solid in 50% 
yield. 1H NMR (400 MHz, DMSO): δ  2.00-2.10 (m, 2H), 2.87-2.96 (m, 2H), 4.06 (s, 
1H), 6,14 (s, IH), 6.77 (d, J=2.4, 1H), 6.86 (dd, J=8.8 Hz, 2.4, 1H), 7.69 (d, J=8.8 Hz, 
1H), 8.60 (s, 2H), 10.73 (s, 1H) 1H NMR (400 MHz,D2O): δ 1.89-1.94 (m, 2H), 2.43-
2.54 (m, 2H), 3.88 (t, J=6.2 Hz, 1H), 5.77 (s, 1H), 6.11 (s, 1H), 6.40 (d, J=8.8 Hz, 1H), 
7.03 (d, J=8.0 Hz, 1H). 13C NMR (100MHz, CDCl3): δ 27.45, 29.27, 52.19, 103.13, 
110.23, 111.43, 113.62, 126.76, 155.68, 160.81, 161.88, 171.15. ESI-MS for C13H14NO5 
(M – H+) 262.06 (M+H+) 264.08. 
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Site-directed mutagenesis 
Selection of incorporation sites 
 Energy minimization using CNS NAMD and the sequence alignments Dr. 
Kantrowitz selected two positions on the regulatory chain, E52 and L58, which are close 
enough to the allosteric binding pocket to assure sensitivity of the fluorescent probe as a 
result of any changes due to the binding of the allosteric effectors binding (Figure 4.1). 
 
Plasmids 
The holoenzyme ATCase E52Z and L58Z mutants were constructed using the 
QuikChange Site-directed Mutagenesis kit (Stratagene) with plasmid pEK351 as the 
template for the ATCase holoenzyme. Mutagenesis was performed according to the 
instruction manual for the QuikChange kit. Primers 698 and 699 were used to create 
plasmid pEK664 for E52Z, and 700 and 701 resulted in plasmid pEK665 for L58Z. The 
resulting double-stranded plasmids were isolated with the QIAprep Spin Miniprep Kit 
(Qiagen), and sequenced to confirm the mutations. Once the TAG codon was introduced in 
the regulatory chain of ATCase, Kimberly Gryncel designed the expression system. This 
system involved another mutation performed with primers 710 and 711, as described above, 
with plasmids pEK664 and pEK665 to introduce an NcoI site to create pEK679 and 
pEK680, respectively. Finally, the ATCase genes (PyrB_his_tag and pyrI) from pEK679 
and pEK680 were ligated to plasmid pBAD/JYAMP-4TAG-Myo using NcoI and KpnI 
sites to result in new plasmids, pEK684 to express E52Z and pEK685 to express L58Z 
(Figure 4.2). This plasmid design was also applied to express wild-type holo ATCase in  
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Figure 4.1. A) Surface of ATCase mutant E52Z with CTP in the allosteric binding site. 
The electrostatic potentials of the hydroxycoumarin side chain are mapped onto the 
surface.  B) ATCase mutant L58Z with CTP bound. 
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order to test its viability (plasmid pEK678 and pEK683 were used). To express the 
regulatory chain only of E52Z and L58Z, Kimberly Gryncel designed two new plasmids 
pEK688 and pEK689 from pEK684 and pEK685, respectively, by mutating the 5’ NcoI 
site to an NdeI site using primers 718 and 719. The other NdeI site that follows the Kpnl 
site at 3’ was removed and the catalytic chain was then cut out using the newly formed 
NdeI sites to create plasmids pEK692 to express E52Z_R only and pEK693 for L58Z_R 
only mutant.  These modifications were also performed on pEK683 to obtain pEK687 in 
the first step and pEK691, lastly, which contains only the wild-type R chain. All plasmid 
maps can be seen on Figures 4.2-4.4. 
 
Table 4.1. Sequences of mutagenesis primers 
ID # Name Sequence 
698 ES2Z C CTG CCT TCT GGC TAG ATG GGC CGC 
699 ES2Z rev. comp. Reverse complement  
700 
 
L58Z 
 
CT GGC GAG ATG GGC CGC AAA GAT TAG ATC 
AAA ATC GAA AAT ACC  
701 L58Z rev. comp. Reverse complement 
710 
 
NCoI 
(351,664,665) 
GCCCAGGCGTCAGGAGATAAACCATGGCTA 
ATCCGCTATATCAG 
718 R chain NcoI 
(351) 
5'-CGT TTT TTG GGC TAA CAG GAG GAA TTA 
CAT ATG GCT AAT CCG CTA TAT CAG AAA CAT 
ATC 
719 718 rev. comp. Reverse complement of 718  
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Figure 4.2. Plasmid maps 
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 89 
 
 
 
Figure 4.3. Plasmid maps 
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Figure 4.4. Plasmid maps 
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Expression of mutants E52Z and L58Z of ATCase 
Overexpression and Purification 
The enzymes were isolated from E. coli Top10 cells containing pBKCouRS-D8 
(pBK-JYRS) and pEK684 for the ATCase E52Z mutant or pEK685 for the L58Z mutant. 
Cells were grown in YT (5 mL) supplemented with kanamicyn (50 µg/mL) and 
tetracycline (12.5 µg/mL). Starter culture (1 mL) was used to inoculate 500 mL of 
glycerol minimum media (receipt) supplemented with the mentioned antibiotics and L-(7-
hydroxycoumarin-4-yl) ethylglycine (1.5 mM). Cells were grown at 37 ºC to an OD600 of 
0.6 and the expression was induced with 0.2% arabinose and L-(7-hydroxycoumarin-4-
yl) ethylglycine (0.5 mM). The culture was incubated overnight at 37 ºC with agitation. 
The cells were harvested by centrifugation, re-suspended in 0.1 M Tris, pH 9.2 and lysed 
by sonication. The regulatory chain of E52Z was isolated also from Top10 cells 
containing pBKCouRS-D8 and pEK692 and grown under the conditions explained 
above. The harvested cells were re-suspended in 0.1 M Tris, 0.1 mM ZnCl, pH 9.2 and 
lysed by sonication. The overexpressed E52Z and L58Z mutants were purified using Ni2+ 
column pre-equilibrated with a 50 mM Tris, 200 mM NaCl buffer, pH 8.3. The proteins 
were eluted with 50 mM Tris, 200 mM NaCl buffer containing 400 mM imidazole, pH 
8.3. Fractions containing the respective mutant enzymes, as assessed by SDS-PAGE gel 
electrophoresis, were combined and dialyzed against 50 mM Tris=acetate, 2 mM 2-
mercaptoethanol, pH 8.3. Samples were then subjected to a Phenyl Sepharose Fast Flow 
resin, pre-equilibrated with 20% ammonium sulfate, 50 mM Tris=acetate, 2 mM 2-
mercaptoethanol, 0.1 mM Zn, pH 8.3 and elution with 50 mM Tris=acetate, 2 mM 2-
mercaptoethanol, 0.1 mM Zn, pH 8.3, to purify enzymes further. Anion-exchange 
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chromatography, using Q-sepharose Fast Flow resin followed by Source-Q pre-
equilibrated with 50 mM Tris=acetate, 2 mM 2-mercaptoethanol, 0.1 mM ZnCl, pH 8.3 
to elution with 50 mM Tris=acetate, 2 mM 2-mercaptoethanol, 0.1 mM ZnCl, 1 M NaCl, 
pH 8.3 buffers, was applied to purify E52Z_R only. Fractions containing mutant ATCase 
R chain were combined and lastly subjected to a Phenyl Sepharose Fast Flow resin, pre-
equilibrated with 20% ammonium sulfate, 50 mM Tris=acetate, 2 mM 2-
mercaptoethanol, 0.1 mM Zn, pH 8.3 and elution with 50 mM Tris=acetate, 2 mM 2-
mercaptoethanol, 0.1 mM Zn, pH 8.3. Fractions containing pure E52Z_R only were 
dialyzed against 50 mM Tris=acetate, 0.1 mM ZnCl, 2 mM 2-mercaptoethanol, pH 8.3. 
Purity of enzymes was confirmed by nondenaturing PAGE1,2 and SDS-PAGE.3  
 
Determination of Protein Concentration 
The concentration of the wild-type holoenzyme was determined by absorbance 
measurements at 280 nm with an extinction coefficient of 0.59 cm2mg-1.4 The Bio-Rad 
version of the Bradford dye binding assay was used for determination of the 
concentration of the mutant enzymes and the regulatory chain using wild-type enzyme as 
a standard.5  
 
E52Z and L58Z studies  
Colorimetric Assays 
 The activity of the enzymes was measured by either the colorimetric6 or pH-stat7 
method at 25° C. Colorimetric assays were preformed at pH 8.3, in 50 mM Tris acetate 
buffer. All of the saturation kinetics in the colorimetric assays were determined in 
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duplicate, and the data points shown are the average values. Data analysis for the steady-
state kinetics was carried out as previously described.8 The experimental data were fit to 
theoretical equations using non-linear regression. When significant substrate inhibition 
was present, the data were analyzed using an extension of the Hill equation that included 
a term for substrate inhibition.9 The nucleotide saturation curves were fit to a hyperbolic 
binding isotherm by non-linear regression. 
 
Fluorescent Measurements  
Fluorescent measurements were performed at pH 8.3 with 50 mM Tris=acetate 
buffer, and at pH 7 with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) using a 2-ml, 1-cm cuvette, and a magnetic stir bar to assure proper mixing. 
Measurements were performed with an enzyme concentration of 0.1 to 0.2 mg/ml in the 
presence and absence of CP at a saturating concentration (9.6 mM). After preparing the 
cuvette as mentioned for each fluorescent ATCase mutant, the effects of nucleotide 
binding were measured by incremental addition of the NTPs’ concentration from 0 mM 
to 30 mM as shown in Table 4.3 and measuring the emission spectrum after every 
variation in concentration.  
The stock NTP solutions, with concentrations as shown in Table 4.3, were 
prepared by dissolving the NTP in water, neutralizing to about pH 7 with NaOH, and 
reading absorbance of a suitable dilute sample at the λmax (Table 4.2) for pH 7.   
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Table 4.2. NTPs’ λmax and molar absorptivities 
Triphosphate λmax (nm) at pH 7 - 10 Molar absorptivity (L/mol.cm) 
rATP or dATP 259 15400 
rCTP or dCTP 272 9100 
rUTP 262 10000 
 
 
Table 4.3. Preparation of fluorescent measurements 
NTP (mM) 20 mM NTP 
(µL) 
50mM NTP 
(µL) 
500mM NTP 
(µL) 
900 mM NTP 
(µL) 
0.01 1     
0.05  1.6   
0.1  2.01   
0.4   1.20  
0.7   1.21  
1   1.21  
3    6.27 
7    0.05 
10    6.95 
15    11.60 
20    11.80 
25    12.00 
30    12.21 
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Synthesis of Caged Asp 
Synthesis of 4-methoxyindoline 5 
 To a solution of 4-methoxyindole (0.3 g, 2.03 mmol) in acetic acid (3 mL), was 
added sodium cyanoborohydride (2.24 mL of 1 N THF) at 12º C. After 18 h, the solvent 
was removed and the pH of the reaction was adjusted to 14. Water (3 mL) was added to 
the reaction mixture and the product was extracted with dichloromethane. The organic 
layer was dried over sodium sulfate and the solvent was reduced to afford 100% 
conversion. 1H NMR (400 MHz, CDCl3): δ 2.99 (t, J=8.4 Hz, 2H), 3.55 (t, J=8.4 Hz, 
2H), 3.80 (s, 3H), 6.30 (dd, J=8.2 Hz, 2 Hz, 2H), 6.99 (t, J=8.0 Hz, 1H). ESI for 
C9H11NO (M + H+) 150.08. 
 
Synthesis of (S)-tert-butyl 2-(tert-butoxycarbonylamino)-4-(4-methoxyindolin-1-yl)-4-
oxobutanoate 6 
To a solution of 5 (2.03 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
(0.285 g / 0.325 mL, 1.85 mmol) and DMAP (0.52 g, 3.7 mmol) in anhydrous acetonitrile 
(6 mL), was added Boc-Asp-OtBu (0.607 g, 2.1 mmol) in anhydrous acetonitrile (3 mL). 
The reaction mixture was stirred overnight. The solvent was reduced under vacuum. The 
crude product, dissolved in ethyl acetate, was washed with 0.5 M HCl, saturated aq. 
NaHCO3 and brine. The solvent was dried over sodium sulfate and evaporated. The crude 
residue was purified by flash chromatography on silica gel using 10-25% ethyl acetate in 
hexane as solvent system to afford 70% yield. 1H NMR (400 MHz, CDCl3): δ 1.41 (s, 
9H), 1.42 (s, 9H), 2.80 (dd, J=13.2 Hz, 3.6 Hz, 1H), 3.05-3.14 (t + dd, 3H), 3.80 (s, 3H), 
4.00 (t, J=8.4 Hz, 2H), 4.43-4.47 (m, 1H), 5.80 (d, J=8.8 Hz, 1H), 6.55 (d, J=7.6 Hz, 
1H), 7.12 (t, J=8.2 Hz, 1H), 7.76 (d, J=8.0 Hz, 1H).  13C NMR (100MHz, CDCl3): δ 
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25.26, 28.08, 28.54, 29.86, 38.49, 48.55, 50.73, 79.66, 81.98, 106.26, 110.07, 118.42, 
129.04, 144.06, 155.83, 155.91, 168.57, 170.56. ESI for C22H32N2O6 (M + H+) 421.21. 
 
Synthesis of (S)-2-amino-4-(4-methoxy-7-nitroindolin-1-yl)-4-oxobutanoic acid 7 
 The protected aspartate derivative (0.5 mg, 1.2 mmol) was added to a stirred 
solution of sodium nitrate (0.130 g, 1.2 mmol) in TFA (5 mL) and the mixture was stirred 
for 1 hour at -15º C. The solution was concentrated under vacuum and the residue oil was 
redissolved in water (50 mL). The pH of the aq. solution was adjusted to 6.7 and this was 
washed with ether. The aqueous layer was analyzed by reversed-phase HPLC (mobile 
phase 100% to 60% buffer A, 1 mL/min flow rate, over 15 min) to show two peaks with 
tR 13.24 and 13.48 min at 24% buffer B. The rest of the solution was applied to a semi-
preparative HPLC at 8 mL/min flow rate. The column was first eluted with one column-
volume of 100% buffer A, then with half one-column-volume 100% to 80% buffer A, to 
two column-volumes of 80% to 60% buffer A. Fractions containing the first peak were 
colleted at tR 16.27 min in 23% buffer B. Fractions were combined and lyophilized to 
afford 15% of brown solids. 1H NMR (400 MHz, D2O): δ 3.02 (t, J=8.0 Hz, 2H), 3.30 
(JH2=5.6 Hz, 1.8 Hz, 1H) , 3.38 (JH2=4.4 Hz, 1.8 Hz, 1H), 3.90 (s, 3H), 4.24 (t, J=8.0 Hz, 
2H), 4.37 (t, J=5.0 Hz, 1H), 6.80 (d, J=8.8 Hz, 2H), 7.58 (t, J=9.2 Hz, 2H). 13C NMR 
(100MHz, CDCl3): δ 25.93, 34.89, 49.79, 50.43, 56.32, 108.28, 123.86, 125.65, 134.30, 
135.00, 159.53, 169.26, 171.13. ESI for C22H32N2O6 (M + H+) 310.10. 
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